A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

Cancer Clinical Trial

Official title:

A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02646852
• Other study ID #: D15-11073
• Status: Completed
• Phase: Phase 1
• Start date: March 2016
• Est. completion date: July 2023

Study information

• Verified date: January 2019
• Source: ProLynx LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I, open-label, two-arm, dose escalation study of PLX038 intravenous infusion administered to patients with refractory or relapsed solid tumors. This study will explore two different dosing schedules: Arm 1, once every 3 week (q3w), and Arm 2, once weekly for 2 consecutive weeks of a 4-week cycle.

Description:

PLX038 is an investigational drug product that has demonstrated reasonable antitumor activity in preclinical colorectal, gastric and lung tumor models in animals. This is a first in human trial to determine the maximum, safest dose of PLX038 IV that can be administered to patients either once every 3 weeks or once every 2 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: July 2023
• Est. primary completion date: February 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically (or cytologically)-confirmed diagnosis of solid tumor, refractory after standard therapy for the disease or for which conventional systemic therapy is not reliably effective or no effective therapy is available.

• Aged = 18 years.

• ECOG Performance Status of 0 or 1.

• Adequate clinical laboratory values defined as:

• absolute neutrophil count = 1.5 × 10^9/L

• platelets = 100 × 10^9/L

• hemoglobin = 9.0 g/dL (transfusions permissible)

• plasma creatinine = 1.5 × upper limit of normal (ULN) for the institution or calculated clearance = 60 mL/min (Cockcroft-Gault formula)

• bilirubin = 1.5 × ULN

• alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 × ULN (< 5 x ULN if documented hepatic metastases)

• Serum sodium, potassium, magnesium and calcium within normal limits for the institution (supplements may be given to correct values)

• Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.

• Patients may have measurable or non-measurable disease as defined by RECIST 1.1.

• Signed informed consent prior to the start of any study specific procedures.

• Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.

Exclusion Criteria:

• Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or 5 half-lives for targeted therapies prior to this study entry.

• Have not recovered from adverse events (must be grade =1) due to agents administered more than 4 weeks earlier.

• Known hypersensitivity to any study drug component.

• Extensive prior radiotherapy, more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.

• Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance.

• Pregnant or lactating individuals.

• Current malignancies of another type, with the exception of adequately treated in situ cervical cancer and basal cell skin cancer or other malignancies with no evidence of disease for 2 years or more.

• Known history of HIV, HBV or HCV infection.

• Documented or known bleeding disorder.

• Requirement for anticoagulation treatment that increases INR or aPTT above the normal range (low dose DVT or line prophylaxis is allowed).

• Clinically evident CNS metastases or leptomeningeal disease not controlled by prior surgery or radiotherapy; history of seizure disorder not controlled by anti-seizure medication at the time of enrollment. Patients with primary CNS malignancies are excluded.

• Patients with a significant cardiovascular disease or condition, including:

• Myocardial infarction within 6 months of study entry

• NYHA Class III or IV heart failure

• Uncontrolled dysrhythmias or poorly controlled angina.

• History of serious ventricular arrhythmia (VT or VF, = 3 beats in a row) and/or risk factors (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)

• Baseline prolongation of QT/QTc interval (repeated demonstration of QTc = 450 msec for men and 470 msec for women), or LVEF = 40% by MUGA or ECHO.

• History of clinically significant gastrointestinal bleeding, colitis, or gastrointestinal perforation.

• Patients who require treatment with UGT1A1 inhibitors during the period of investigational treatment with DFP-13318.

• Patients with known Gilbert's syndrome or reduced UGT1A1 activity.

Related Conditions & MeSH terms

• Cancer
• Neoplasms
• Tumors

Intervention

Drug:
• PLX038

Locations

Country	Name	City	State
United States	University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
ProLynx LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with adverse events as a measure of safety and tolerability of PLX038	Toxicity will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 4.03). Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.	Continuous starting on day of first dose (Day 1) up to 30 days after last dose